Mashup Score:53
ReutersCancer vaccines poised to unlock ‘new treatment paradigm’ with Merck/Moderna data - 2 days
Mashup Score:53
Twitter Feed: Reuters Health
Mashup Score:12
ReutersUS FDA approves Pfizer’s RSV vaccine - 1 week
Mashup Score:12
The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc’s respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot...
-
The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors. https://t.co/W3vZWnUMk9 - view on twitter
Mashup Score:11
ReutersUS FDA approves Pfizer’s RSV vaccine - 1 week
Mashup Score:11
The U.S. Food and Drug Administration (FDA) on Wednesday approved Pfizer Inc’s respiratory syncytial virus (RSV) vaccine for older adults, making it the second...
-
The U.S. Food and Drug Administration (FDA) on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors. https://t.co/usLfcYrkGB - view on twitter
Mashup Score:9
ReutersCancer vaccines poised to unlock ‘new treatment paradigm’ with Merck/Moderna data - 3 days
Mashup Score:9
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by...
-
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday. https://t.co/I2jPPadS28 - view on twitter
Mashup Score:9
ReutersAstraZeneca’s Tagrisso slashes death risk in certain post-surgery lung cancer patients - 4 days
Mashup Score:9
AstraZeneca’s lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who...
-
AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed. https://t.co/v9tGALp6VY - view on twitter
Mashup Score:8
ReutersBioNTech says drug from OncoC4 partnership shows promise in mid-stage trial - 6 days
Mashup Score:8
BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink...
-
BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink tumours in close to 30% of participants in a mid-stage lung cancer trial. https://t.co/SlM1yo7S1m - view on twitter
Mashup Score:7
ReutersAstraZeneca’s Tagrisso slashes death risk in certain post-surgery lung cancer patients - 3 days
Mashup Score:7
AstraZeneca’s lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who...
-
AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed. https://t.co/1MuEtWP9hy - view on twitter
Mashup Score:6
ReutersNovartis drug cuts recurrence risk by 25% in early-stage breast cancer - 6 days
Mashup Score:6
Novartis breast cancer drug Kisqali cut the risk of recurrence by a little more than 25% in a pivotal trial on women diagnosed at...
-
Novartis breast cancer drug Kisqali cut the risk of recurrence by a little more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and challenging strong rival Eli Lilly . https://t.co/fDY9phAlxy - view on twitter
Mashup Score:6
ReutersAstraZeneca’s Tagrisso slashes death risk in certain post-surgery lung cancer patients - 3 days
Mashup Score:6
AstraZeneca’s lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who...
-
AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed. https://t.co/doxvFjXOFA - view on twitter
Mashup Score:5
ReutersCancer vaccines poised to unlock ‘new treatment paradigm’ with Merck/Moderna data - 2 days
Mashup Score:5
Adding an experimental mRNA-based vaccine from Moderna and Merck reduced the risk that the most deadly skin cancer would spread by 65% over treatment...
-
Adding an experimental mRNA-based vaccine from Moderna and Merck reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a trial. https://t.co/A8tuOkcoZO - view on twitter
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by...
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday. https://t.co/qsSMXqYuHm - view on twitter